Lactoferrin-modified MSC-derived extracellular vesicles facilitate BBB penetration and enhance gastrodin-induced neuroprotection in Parkinson's disease: involvement of mitophagy.
Lactoferrin-modified extracellular vesicles improved the brain delivery of gastrodin and showed neuroprotective effects in mouse models of Parkinson's disease.
Where it sits
this study against the rest of the adamax corpusSummary and findings
This study developed a lactoferrin-modified extracellular vesicle (EV) delivery system for gastrodin (Gas) to enhance its delivery across the blood-brain barrier (BBB) in Parkinson's disease (PD). The system was tested in an MPTP-induced PD mouse model. The findings suggested improved brain accumulation of Gas and neuroprotective effects.
Abstract
<h4>Background</h4>The blood-brain barrier (BBB) severely impedes neuroprotective agent delivery to the brain in Parkinson's disease (PD). Although gastrodin (Gas) possesses neuroprotective properties, its efficacy is limited by poor BBB permeability. This study aimed to develop a brain-targeted extracellular vesicle (EV) delivery system for Gas and elucidate its neuroprotective mechanisms.<h4>Methods</h4>A brain-targeted EV delivery system was developed using mesenchymal stem cell-derived EVs modified with lactoferrin (Lf). Gas was loaded into Lf-EVs via sonication to construct Lf-EVs-Gas nanocomplexes. The nanocomplexes were characterized by transmission electron microscopy, western blotting, and nano-flow cytometry. <i>Trans</i>-Barrier transport was evaluated using an in vitro Transwell BBB model (hCMEC/D3 cells), while therapeutic efficacy and biodistribution were assessed in an MPTP-induced PD mouse model.<h4>Results</h4>Lf-EVs-Gas exhibited a typical cup-shaped morphology, with a mean size of 79.08 nm and a drug loading efficiency of 47.08 ± 4.63%. Lf functionalization significantly enhanced BBB transport, achieving a brain Gas concentration of 10.34 ± 2.7 ng/g in PD mice versus undetectable levels for free Gas. The targeted system demonstrated superior brain accumulation versus non-targeted vesicles. In 6-OHDA-treated SH-SY5Y cells and MPTP-induced PD mice, the system upregulated tyrosine hydroxylase, reduced α-synuclein aggregation, inhibited neuronal apoptosis, and improved motor function. Mechanistically, these protective effects of Lf-EVs-Gas were associated with activation of PINK1-related mitophagy, as evidenced by elevated LC3-II/LC3-I ratio and increased TOMM20/LC3 colocalization.<h4>Conclusion</h4>Lf-EVs-Gas enhanced the brain delivery of Gas and produced neuroprotective effects in cellular and mouse toxin-based models of PD. These effects were associated with the activation of PINK1-related mitophagy, supporting Lf-modified EVs as a promising brain-targeted delivery platform for Gas. Further studies establishing mechanistic causality, long-term safety, and efficacy in progressive PD models are warranted.
Background
This paper addresses the challenge of delivering neuroprotective agents across the blood-brain barrier (BBB) in Parkinson's disease (PD). Previous studies have indicated that gastrodin (Gas) has neuroprotective properties, but its clinical application is limited due to poor BBB permeability. The development of a targeted delivery system using lactoferrin-modified extracellular vesicles (Lf-EVs) aims to enhance the brain delivery of Gas and elucidate its neuroprotective mechanisms.
Methods
The study utilized a brain-targeted EV delivery system developed from mesenchymal stem cell-derived EVs modified with lactoferrin. Gastrodin was loaded into these Lf-EVs via sonication. The efficacy of the delivery system was evaluated using an in vitro Transwell BBB model and in an MPTP-induced PD mouse model, focusing on therapeutic efficacy and biodistribution.
Results
The primary endpoint showed that Lf-EVs-Gas achieved a brain Gas concentration of 10.34 ± 2.7 ng/g in PD mice, compared to undetectable levels for free Gas. The study also reported a drug loading efficiency of 47.08 ± 4.63%. Additionally, the Lf-EVs-Gas system was associated with upregulation of tyrosine hydroxylase and activation of PINK1-related mitophagy, as indicated by elevated LC3-II/LC3-I ratios.
Interpretation
The findings suggest that Lf-EVs-Gas may improve the delivery of gastrodin to the brain and provide neuroprotective effects, which aligns with previous literature on the importance of BBB penetration for neuroprotective agents. However, the clinical significance of the observed effects remains uncertain, particularly given the reliance on animal models and the need for further validation in human studies. The study's limitations, including small sample sizes and the absence of long-term safety data, may confound the conclusions drawn.
Key findings
- mean size of 79.08 nm for Lf-EVs-Gas
- drug loading efficiency of 47.08 ± 4.63%
- brain Gas concentration of 10.34 ± 2.7 ng/g in PD mice versus undetectable levels for free Gas
- upregulated tyrosine hydroxylase in 6-OHDA-treated SH-SY5Y cells and MPTP-induced PD mice
- elevated LC3-II/LC3-I ratio indicating mitophagy activation
Limitations
- animal model study, not human data
- small sample size in animal studies
- short follow-up duration
- no long-term safety data reported
- mechanistic causality not established